CN Patent

CN115806529A — Psma结合剂及其用途

Assigned to Shandong Viwit Baike Pharmaceutical Co ltd · Expires 2023-03-17 · 3y expired

What this patent protects

本发明提供了具有式I所示结构的化合物或其药学上可接受的盐、酯或溶剂化物，包括所述化合物或其药学上可接受的盐、酯或溶剂化物作为配体和放射性核素的放射性标记的配合物，及其用途。与现有化合物相比，本发明的化合物在肿瘤靶向性能、药代动力学、调节化合物的亲脂性等方面具有更好的效果。

USPTO Abstract

本发明提供了具有式I所示结构的化合物或其药学上可接受的盐、酯或溶剂化物，包括所述化合物或其药学上可接受的盐、酯或溶剂化物作为配体和放射性核素的放射性标记的配合物，及其用途。与现有化合物相比，本发明的化合物在肿瘤靶向性能、药代动力学、调节化合物的亲脂性等方面具有更好的效果。

Drugs covered by this patent

lutetium-lu-177-vipivotide-tetraxetan (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN)

Patent Metadata

Patent number: CN115806529A
Jurisdiction: CN
Classification: —
Expires: 2023-03-17
Drug substance claim: No
Drug product claim: No
Assignee: Shandong Viwit Baike Pharmaceutical Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.